DR. HAIFA SHEN (2015 AWARD)
Harnessing Vascular and Cellular Depots of Nanotherapeutics for the Treatment of Metastatic Breast Cancer

Outcomes: Below are major achievements from the METAvivor-funded project:
1. Publication: We are currently summarizing data from this project, and will submit a manuscript for publication. METAvivor will be acknowledged as one of the funding supports for the overall study.
2. Funding support: Preliminary data from the METAvivor-funded project was used as supporting information in a grant proposal to the National Cancer Institute early this year. The overall goal of the application is to study mechanism of particulate drug transport inside the tumor tissue. This R01 grant has been funded.
3. Clinical relevance: iNPG-pDox is currently in the stage of investigational new drug (IND)-enabling studies. It is expected to reach clinical trial within 12 months for treatment of metastatic breast cancer.